ATTORNEY ADVERTISING

< Home >

Search By:

Products

Injury

Topic

Company

Industry

As a Web 2.0 application, ClassAdvocate.com currently employs JavaScript to provide advanced search and display functionality. It appear that you currently do not have JavaScript enabled on your browser and will not be able to navigate the site at this time.

Please ensure that you have JavaScript enabled to continue.

Amgen's Aranesp might increase risk of death and rapid tumor growth.

Click here if you have had similar experiences as those affected by this investigation.

Investigation Source

Beasley, Allen, Crow, Methvin, Portis & Miles, P.C.

218 Commerce Street
Montgomery, AL 36104

Investigation Scope

Nationwide

Category Information

Investigation Topic

Increased Risk of Bodily Injury

Product or Service

Aranesp

Injury Types

Death
Breast Cancer
Cervical Cancer
Accelerated Rate of Tumor Growth

Investigation Details

Aranesp is an Erythropoiesis Stimulating Agents (ESAs). ESAs are used to treat the blood-disorder anemia in patients with kidney failure or who are undergoing chemotherapy. The Food and Drug Administration warned that the drug increases death and accelerate tumor growth in patients with several types of cancer, including breast and cervical. Prior labeling added to the drugs in 2007 warned of similar risks in other types of cancers. The warnings apply to drugmaker Amgen's Aranesp and Epogen, as well as Procit, sold by Johnson & Johnson. Labeling approved by FDA said risks occurred when doctors treated patients with elevated levels of the drugs, which stimulate red blood cell levels.

Do not change medications without first consulting your doctor.

Defendant Details

Name (Stock Symbol)	Brief Description
Amgen Inc. (AMGN)	Amgen is a Fortune 500 biotechnology company

Click here if you have had similar experiences as those affected by this investigation.

< Terms and Conditions >< Disclaimers >< Contact Us >

The information provided on ClassAdvocate.com is general in nature, does not apply to any particular factual situation, and is not and should not be taken as legal or other professional advice. We make no commitment or warranty that the factual, legal or any other information on ClassAdvocate.com, or on any linked website, is accurate, complete, error-free, or current. As such, you should not rely on such information, and should seek professional advice if and as you determine appropriate. ClassAdvocate.com is not a lawyer referral service, and no attorney-client or confidential relationship is or should be formed by use of the site. The investigations listed on ClassAdvocate.com are attorney advertisements and do not in any way constitute a referral or endorsement by ClassAdvocate.com or any approved or authorized lawyer referral service.